Lv1
6 积分 2024-11-01 加入
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
1个月前
已完结
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
2个月前
已完结
A heterogeneous subtype of biliary epithelial senescence may be involved in the pathogenesis of primary biliary cholangitis
2个月前
已完结
Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes
2个月前
已完结
How bile acids and the microbiota interact to shape host immunity
2个月前
已完结
Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer
2个月前
已完结
The phenotypic and functional characteristics of intrahepatic CD69+CD103+ tissue-resident MAIT cells in primary biliary cholangitis
3个月前
已完结
皖公网安备34019202002308
